Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer. Eighty-seven patients with unresectable non-small-cell lung cancer took part in the study. Seventy-seven were evaluable for response. Of these, 60%...

Descripción completa

Detalles Bibliográficos
Autores principales: Pujol, J. L., Monnier, A., Berille, J., Cerrina, M. L., Douillard, J. Y., Rivière, A., Grandgirard, A., Gouva, S., Bizzari, J. P., Le Chevalier, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969429/
https://www.ncbi.nlm.nih.gov/pubmed/8198982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969429/
https://www.ncbi.nlm.nih.gov/pubmed/8198982

Ejemplares similares